4Q19 Earnings Conference Call February 20, 2020 ITGR: 4Q19 Earnings - - PowerPoint PPT Presentation

4q19 earnings conference call
SMART_READER_LITE
LIVE PREVIEW

4Q19 Earnings Conference Call February 20, 2020 ITGR: 4Q19 Earnings - - PowerPoint PPT Presentation

4Q19 Earnings Conference Call February 20, 2020 ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 1 Integer Holdings Corporation Fourth Quarter 2019 Earnings Conference Call 9 a.m. Eastern Time, February 20, 2020 A webcast of


slide-1
SLIDE 1

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 1

4Q19 Earnings Conference Call

February 20, 2020

slide-2
SLIDE 2

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 2

Integer Holdings Corporation

Fourth Quarter 2019 Earnings Conference Call 9 a.m. Eastern Time, February 20, 2020 Speakers: Joe Dziedzic President and Chief Executive Officer Jason Garland Executive Vice President, Chief Financial Officer Tony Borowicz Senior Vice President, Strategy, Corporate Development & Investor Relations

  • A webcast of today’s call can be accessed

in the “Investors” section of the Company’s website: http://investor.integer.net

  • To participate on the call, please dial:
  • 833-236-5762 (U.S.)
  • 647-689-4190 (International)
  • The conference ID is 8069250
  • An online archive of the broadcast will be

available at the website three hours after the live call, and will be available through Thursday, February 27, 2020, by dialing

  • 800-585-8367 (U.S.)
  • 416-621-4642 (International)
  • The conference ID is 8069250
slide-3
SLIDE 3

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 3

Presentation of Financial Information & Forward-Looking Statements

Important Information This presentation contains summarized information concerning Integer Holdings Corporation (the “Company”) and its business,

  • perations, financial performance and trends. The historical financial and operating data contained herein reflect the consolidated

results of the Company for the periods indicated. No representation is made that the information in this presentation is complete. For additional financial and business-related information, as well as information regarding business and product line trends, see the Company’s most recent Annual Report on Form 10-K (“Form 10-K”) and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”), as well other reports filed with the SEC from time-to-time. Such reports are or will be available in the investor relations section of our corporate website (investor.integer.net) and the SEC’s website (www.sec.gov). Non-GAAP Financial Measures. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include adjusted net income, adjusted diluted earnings per share, earnings before interest taxes depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted sales, and organic growth rates should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of these non-GAAP financial measures to the most comparable GAAP measures, please refer to the appendix to this presentation and the earnings release associated with this period which can be found in the investor relations section of our corporate website (investor.integer.net). Forward Looking Statements. Some of the statements contained in this presentation whether written or oral may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to future sales, expenses, profitability, cash flows, debt repayments and leverage; expected growth of our business and industry; our ability to execute our business model and our business strategy; our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets; our ability to repay existing indebtedness; projected capital expenditures; our expected tax rates; and other events, conditions or developments that will or may occur in the future. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “see,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are based on the Company’s current expectations and speak only as of as of the date of this presentation. The Company’s actual results could differ materially from those stated or implied by such forward-looking statements. Except as may be required by law, the Company assumes no obligation to update forward-looking information, including information in this presentation, to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects.

slide-4
SLIDE 4

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 4

Agenda

  • Opening Comments
  • Strategy Update
  • Financial Results
  • Product Line Review
  • 2020 Outlook
  • Question & Answer Period
slide-5
SLIDE 5

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 5

Opening Comments

slide-6
SLIDE 6

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 6

4Q Financial Results

  • +7% sales growth … solid growth in all product lines
  • Adj. EBITDA +8%, Adj. EPS +20%
  • Debt leverage below 3 times Adjusted EBITDA

Full-Year Financial Results

  • +4% sales growth … at low end of original guidance growth rate
  • Adj. EBITDA +9%, Adj. EPS +23% … exceeded original guidance
  • Paid $117 million debt … exceeded original guidance

Strong 2019 Financial Results …

All product lines posted solid sales growth Achieved two strategic

  • bjectives: grew profit

2x sales growth rate and reduced debt leverage to 2.9x

(1) Guidance as provided during 4Q 2018 earnings call on February 21, 2019

slide-7
SLIDE 7

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 7

Strategy Update

slide-8
SLIDE 8

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 8

Journey to Excellence

Sales Growth versus Prior Year:

*Represents reported change prior to Advanced Surgical and Orthopedic (AS&O) divestiture

(2)% (4)%

2015 2016

2015 2016

Declined Declined >6x

  • Integrated $1.7B Lake

Region acquisition

  • Spun off Nuvectra
  • Challenging customer

relationships

Disruption

* *

5% 7%

2017 2018

2017 2018

Market growth ~1x sales growth 5.6x 3.5x

  • New leadership team
  • Operational stabilization
  • Clear strategy
  • Portfolio change
  • Multi-year plans

Stabilizing & Building

*

Strategy Financial Objectives

  • Sales growth 200 basis

points above market

  • Profit growth 2x sales

growth rate

  • Debt leverage 2.5x - 3.5x

1 2 3

slide-9
SLIDE 9

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 9

Portfolio Strategy Operational Strategy: Strategic Imperatives

How we win in the markets we serve How we achieve excellence in everything we do

Cardio & Vascular Neuromodulation Electrochem Portable Medical

Invest to Grow Protect & Preserve

Cardiac Rhythm Management

Strategy Developed in 2nd half of 2017

slide-10
SLIDE 10

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 10

Business Presidents

Payman Khales President Cardio & Vascular February 2018 Joel Becker President, Cardiac Rhythm Management & Neuromodulation April 2019 Carter Houghton President, Electrochem & Power Solutions May 2019 Kirk Thor Chief Human Resources Officer January 2018 Jason Garland Chief Financial Officer October 2018 Joe Flanagan EVP, Quality & Regulatory Affairs 2012 Jen Bolt SVP, Global Operations 2005 Tony Borowicz SVP, Strategy, Business Development, Investor Relations 2002

Functional Leaders

Joe Dziedzic President & CEO July 2017

Leadership Team In Place

Elizabeth Giddens General Counsel and Chief Ethics & Compliance Officer August 2019

6 new leaders in 2018/2019

slide-11
SLIDE 11

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 11

Building & Strengthening Culture

Investing in Culture Strategic Imperatives 2018 & 2019 Actions

Building Leadership Capability to Deliver Performance Excellence

Leadership Capability Performance Excellence HR Transformation

  • Talent Analytics
  • Talent Review / Evaluation
  • Selection Process
  • Leadership Development
  • Succession Planning
  • Strategic Workforce Planning
  • Associate Engagement
  • Performance Management
  • Total Rewards
  • Organization Effectiveness
  • Selection Process

− Structured Interview Training − 430+ Leaders Trained − 350+ Interviews Conducted

  • Candidate Assessment
  • Individual Development Plans
  • Performance Management

− Psychometric Assessment − 70+ Candidates − Baseline for development plans − 40% of Sr. Leaders/Mgrs − 60% of HiPo’s + Successors − HiPo’s + Successors − Key Role Identification − Compensation Differentiation

1 2 3 4

Headcount +8%  Dollars spend +13% 

slide-12
SLIDE 12

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 12

20 LEAN Diagnosis events Over 200 participants 140 Projects/Kaizen events 120 Site leaders trained +50% +190 bps

July 2018 to December 2019

  • Adj. EBITDA Margin(1)

LEAN Headcount

All sites trained & initial LEAN Diagnosis executed 20.7% 22.6%

Investing in Manufacturing Excellence and LEAN

2017 2019 2019 2017

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

slide-13
SLIDE 13

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 13

Multi-year contracts signed in 2019 +10% improvement +40% improvement

Delivering for Customers

~$425 million

Quality(1) On Time Delivery Sales

(1) Quality metric reflects improvement in customer complaints rate

Annual sales 2017 2019 2017 2019

slide-14
SLIDE 14

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 14

Portfolio & Product Line Strategy

✓ Divested AS&O … $600 million price; EPS accretive day one ✓ Addressed Portable Medical profitability … “Invest to Grow” ✓ Launched Growth Teams in 4Q18 … Defined strategy

process; own development and oversight of execution

Operational Strategic Imperatives

Strategy Execution … Status

Culture

  • Built Leadership

Team

  • Aspire to

Excellence

Cost

  • LEAN

Deployment

  • Operational

Improvements

Customers

  • New Sales

Leadership

  • Adding

Capabilities

slide-15
SLIDE 15

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 15

Debt to Adj. EBITDA Leverage Ratio(1)

Significantly Reduced Debt Leverage

($ in millions)

(1) Leverage Ratio calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by trailing 4 quarter Adjusted EBITDA (2) Net Total Debt shown is total principal amount of debt outstanding less Cash and Cash Equivalents

Net Total Debt(2) $1,719 $1,598 $916 $812

slide-16
SLIDE 16

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 16

Delivered 67% Adjusted Earnings Per Share Growth

$2.81 $4.68 $3.80

Adjusted Earnings Per Share Up $1.87 +67%

Adjusted EPS(1)

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

slide-17
SLIDE 17

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 17

Delivering for Investors … Met or Exceeded Guidance(1)

($ in millions)

$255 $275 to to $259 $283 $2.70 $3.35 $4.05 to to to $3.10 $3.80 $4.25

Adjusted Sales Adjusted EBITDA(2) Adjusted EPS

$1,390 $1,175 $1,260 to to to $1,430 $1,200 $1,280

Guidance

Consistently Delivering on Commitments

$1,213 $1,258 $1,462 $1,131 $259 $284 $295 $234 $3.80 $4.68 $3.09 $2.81

With AS&O Without AS&O

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure (2) Guidance not provided for 2017 Adjusted EBITDA

slide-18
SLIDE 18

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 18

2017 2018 2019

Profit Growth 2x Sales Growth Rate in 2019 … and Beyond

($ in millions)

  • Adj. EBITDA

$234 $259 $284

Continued Progress … Delivered Adj. EBITDA Growth 2.5x Sales Growth in 2019

  • Adj. EBITDA to

sales growth ratio(1)

0.1x 1.5x 2.5x

  • Adj. Sales growth

5% 7% 4%

  • Adj. EBITDA growth

0.1% 11% 9%

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

slide-19
SLIDE 19

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 19

Journey to Excellence

Sales Growth versus Prior Year:

(2)% (4)%

2015 2016

5% 7%

2017 2018

2015 2016 2017 2018

Market growth ~1x sales growth 5.6x 3.5x

  • New leadership team
  • Operational stabilization
  • Clear strategy
  • Portfolio change
  • Multi-year plans

Declined Declined >6x

  • Integrated $1.7B Lake

Region acquisition

  • Spun off Nuvectra
  • Challenging customer

relationships Market growth 2x sales growth 2.9x 2.5x - 3.5x

  • Leadership team complete
  • Executing strategy, including

bolt-on acquisitions

  • Deleveraging

4%

2019 2020

3% - 4%

Disruption Stabilizing & Building Profit Expansion

*Represents reported change prior to AS&O divestiture

* * *

Strategy Financial Objectives Sales growth 200 basis points above market Profit growth 2x sales growth rate Debt leverage 2.5x – 3.5x

1 2 3

slide-20
SLIDE 20

Financial Results

slide-21
SLIDE 21

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 21 (1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

($ in millions, except per share amounts)

Sales Adjusted EBITDA Adjusted Net Income

$326 $73 $68

4Q19 Adjusted Financial Results(1)

$303 $34 $41

Adjusted EPS

% Growth 7% 8% 20% $1.25 $1.04

slide-22
SLIDE 22

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 22

($ in millions, except per share amounts)

Adjusted Sales Adjusted EBITDA Adjusted Net Income

$1,258 $284 $259 $1,213 $124 $154

2019 Adjusted Financial Results(1)

% Growth 4% 9% 24%

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

Adjusted EPS

$4.68 $3.80

slide-23
SLIDE 23

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 23

($ in millions, except per share amounts)

2019 Adjusted Net Income(1)

$3.80 $0.63 $0.02 $0.17 $0.06 $4.68 Adj. EPS

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

slide-24
SLIDE 24

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 24

2019 Actual Results Compared to Original Guidance

Debt Payments

(1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E) (2) Leverage calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by Trailing 4 Quarter Adjusted EBITDA (3) 2019 guidance as provided on February 21, 2019

Cash Flow From Ops Free Cash Flow(1) Leverage(2)

($ in millions, except per share amounts)

Original Guidance(3) Actual Actual Actual Actual

$160 - $170 $165 $110 - $120 $117 $105 - $115 $117 2.5x - 3.5x 2.9x

Original Guidance(3) Original Guidance(3) Original Guidance(3)

Memo: Bus Dev $15

slide-25
SLIDE 25

Product Line Review

slide-26
SLIDE 26

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 26

Cardio & Vascular

Year-over-Year Sales Growth Continues(1)

Trailing 4 Quarters

Integer – Trailing 4 Quarters

(1) Excludes impact from changes in foreign currency exchange rates and US Bio Design Acquisition

Advanced Surgical, Orthopedic & Portable Medical Electrochem (Non-Medical) Cardiac & Neuromodulation

slide-27
SLIDE 27

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 27

Offering a full-range of products and services for catheter-based interventional vascular devices and a suite of supply chain solutions to support the development and manufacturing of complex components, sub-assemblies and finished devices

Steerable Sheaths Catheters & Sheaths Guidewires, Stylets & Accessories Introducers

Reported Trailing 4 Quarter Sales

($ in millions)

Quarterly Adjusted Sales Change(1)

Cardio & Vascular

10% 10% 7% 5% 4%

  • 4Q19 growth led by a strong increase in peripheral vascular

demand from a customer launching existing program into new geography and market growth. Incremental sales from the signing of a customer contract on existing business fully offset the impact of an end of life electrophysiology program

  • Trailing 4 sales quarter driven by strong growth of peripheral

vascular and structural heart, overcoming a ~200 basis points headwind from an end of life electrophysiology program

  • Expect 2020 to be mid-single-digit growth as product

launches ramp and the impact of the end of life electrophysiology program lessens

r ts

Y-o-Y% Change

(1) Excludes impact from changes in foreign currency exchange rates and acquisitions

slide-28
SLIDE 28

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 28

Providing technology solutions for the active implantable medical device industry by partnering with customers to bring high-quality products to established and emerging markets – from initial concept through high-volume manufacturing

Pulse Generator Components & Assemblies Leads & Lead Components, Adaptors & Assemblies Pulse Generators & External Solutions (Programmers, Chargers, Patient Devices)

Reported Trailing 4 Quarter Sales

($ in millions)

CRM & Neuromodulation

4% 4% 2% (1)% 3%

  • 4Q19 growth driven by new and next generation product

launches, underlying strength in existing CRM programs, and a new customer agreement on existing business, partially offset by the Nuvectra Chapter 11 filing

  • Trailing 4 quarter sales increase driven by CRM growth due

to higher market demand and the new customer agreement

  • n existing business, which was partially offset by slight

neuromodulation decline due to the Nuvectra Chapter 11 filing and market contraction

  • Expect slight decline in total for 2020, as double-digit decline

in neuromodulation from Nuvectra bankruptcy offsets low- single-digit growth in CRM

Y-o-Y% Change

(1) Excludes impact from changes in foreign currency exchange rates

Quarterly Adjusted Sales Change(1)

slide-29
SLIDE 29

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 29

Orthopedic Implants & Instruments Core Battery Pack Assemblies Li-Ion Battery Packs Electrosurgical Accessories

Reported Trailing 4 Quarter Sales

($ in millions)

Advanced Surgical, Orthopedics & Portable Medical

Offering a broad portfolio of power solutions and technologies to Portable Medical markets and supporting the divested AS&O product line

14% 7% 1% 0% 1%

  • 4Q19 sales growth driven by increased end-market demand

for Advanced Surgical and Orthopedic base products

  • Trailing 4 quarter sales trend remains relatively flat across all

product lines

  • Expect 2020 mid-single-digit growth with accelerating

Portable Medical demand

Y-o-Y% Change

(1) Excludes impact from changes in foreign currency exchange rates

Quarterly Adjusted Sales Change(1)

slide-30
SLIDE 30

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 30

Enhancing lives worldwide by providing superior power solutions that enable the success and advancement of our customers’ critical applications

Battery Packs Battery Chargers Battery Cells

Reported Trailing 4 Quarter Sales

($ in millions)

Electrochem

(7)% (8)% (4)% 4% 10%

  • 4Q19 growth driven by increased military market

demand and growth in the energy market

  • Trailing 4 quarter sales returning to double-digit growth

driven by strong demand in the military market and high- single-digit growth with energy customers

  • Expect 2020 high-single-digit growth from new product

launches and increased military and environmental demand

Y-o-Y% Change

(1) Excludes impact from changes in foreign currency exchange rates

Quarterly Adjusted Sales Change(1)

slide-31
SLIDE 31

2020 Outlook

slide-32
SLIDE 32

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 32

2020 Sales Outlook

($ in millions)

$59 - $79 $1,290 - $1,310 5% - 6% 3% - 4% (2)% % Growth

Nuvectra Fewer Days in 2020

5 to 6% Growth Offset by 2% Headwinds

Growth Headwinds

Sales

slide-33
SLIDE 33

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 33

2020 Full-Year Outlook(1)

Adjusted EPS

% Growth 3% - 4% 9% - 13%

Sales

6% - 8%

Adjusted EBITDA

$1,258 $4.68 $1,290 - $1,310 $5.10 - $5.30 $284 $300 - $307

($ in millions, except per share amounts)

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

slide-34
SLIDE 34

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 34

Debt Payments

(1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E) (2) Leverage calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by Trailing 4 Quarter Adjusted EBITDA, as of end of each year

Cash Flow From Ops Free Cash Flow(1) Leverage(2)

2020 Cash Flow Outlook

$548 $175 - $185 $105 - $125 $90 - $110 $52 - $72

Divestiture Proceeds Accelerated Repayment Required Repayment

$700 $117

CAPEX

$60 - $70

($ in millions, except per share amounts)

Target 2.5x - 3.5x Memo: Bus Dev $15 $10

$44 $48

slide-35
SLIDE 35

Summary

slide-36
SLIDE 36

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 36

Journey to Excellence

Sales Growth versus Prior Year:

(2)% (4)%

2015 2016

5% 7%

2017 2018

2015 2016 2017 2018

Market growth ~1x sales growth 5.6x 3.5x

  • New leadership team
  • Operational stabilization
  • Clear strategy
  • Portfolio change
  • Multi-year plans

Declined Declined >6x

  • Integrated $1.7B Lake

Region acquisition

  • Spun off Nuvectra
  • Challenging customer

relationships Market growth 2x sales growth 2.9x 2.5x - 3.5x

  • Leadership team complete
  • Executing strategy, including

bolt-on acquisitions

  • Deleveraging

4%

2019 2020

3% - 4%

Disruption Stabilizing & Building Profit Expansion

*Represents reported growth prior to AS&O divestiture

* * *

200 bps above market 2x sales growth 2.5x – 3.5x

“Excellence in everything we do”

Market + 2%

Sales Growth Rate Expansion Strategic Objectives

 

slide-37
SLIDE 37

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 37

R&D Headcount Sales & Marketing $ Spend Capabilities

Chaska, Plymouth +C&V quick-turn  US BioDesign (M&A) +Complex braiding  Salem +Laser machining  2017 2020 2017 2020 +30% +25%

Investing in Capabilities for Growth

Inomec (M&A) +Delivery systems, catheters 

Investing ~$35 million ‘18-’20

+ERP at 4 sites 

slide-38
SLIDE 38

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 38

Salem Montevideo Juarez Tijuana South Tijuana North +Site expansion +Site expansion +Site expansion +Build-out +First IPG device manufacturing site in Mexico, FDA approved +IPG manufacturing capacity

Investing in Capacity for Growth

Investing ~$40 Million 2018 to 2020

slide-39
SLIDE 39

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 39

Attractive Value Proposition

Financial Objectives Status Integer Strategy

Profit growth 2x sales growth rate Profit

  • Strong Leadership Team

2

  • Investing to Execute Strategy

4

  • Clear Strategy

1

  • Delivering Strong Operational

& Financial Results 3

Sales growth 200 bps above market Sales 2.5x – 3.5x adjusted EBITDA Debt Leverage

Earn a valuation premium

slide-40
SLIDE 40

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 40

Questions?

slide-41
SLIDE 41

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 41

APPENDIX

slide-42
SLIDE 42

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 42

4Q19 Adjusted Net Income (1)

($ in millions, except per share amounts)

$1.04 $0.17 $(0.01) $0.05 $0.00 $1.25 Adj. EPS

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure

slide-43
SLIDE 43

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 43

Debt Payments

(1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E) (2) Leverage calculated as total principal amount of debt

  • utstanding less Cash and Cash Equivalents divided by

trailing 4 quarter Adjusted EBITDA (3) 3Q18 Accelerated Repayments totaled $588M; $548M from divestiture proceeds plus $40M from operations

Cash Flow From Ops Free Cash Flow (1)

Accelerated Repayment from Divestiture Proceeds Accelerated Repayment Required Repayment

  • Reduced leverage ratio to

2.9 times adjusted EBITDA

  • No significant maturities

until 2022; well within covenants

Leverage (2)

$595 $40 $548

(3)

2019 Highlights

Cash Flow & Leverage

($ in millions)

slide-44
SLIDE 44

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 44

Adjusted Sales Adjusted EPS

(1) Refer to the appendix of this presentation for a reconciliation of Adjusted Sales and Adjusted EPS to the most directly comparable GAAP measure (2) The quarterly and annual EPS numbers are calculated independently and may not sum to the total (3) Excludes impact of foreign currency reported in other (income)/loss, net Impact of foreign currency reported in other (income)/loss, net Adjusted EPS, as reported

Organic Adjusted EPS(3)

(2)

$265 $313 $305 $303 $280 $285 $301 $292 $315 $314 $304

$(0.05) $(0.01) $0.58 $0.91 $0.98 $0.89 $0.66 $1.01 $1.10 $1.04 $1.00 $1.23 $1.19 $1.26

$326

Historical Financial Results(1)

($ in millions, except per share amounts)

slide-45
SLIDE 45

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 45

2020 Full-Year Outlook

($ in millions, except per share amounts)

slide-46
SLIDE 46

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 46

Non-GAAP Reconciliation

Income from Continuing Operations and Diluted EPS Reconciliation – QTD

See the Footnotes to this table on page 48 of this presentation ($ in thousands, except per share amounts)

slide-47
SLIDE 47

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 47

Non-GAAP Reconciliation

Income from Continuing Operations and Diluted EPS Reconciliation – YTD

See the Footnotes to this table on page 48 of this presentation ($ in thousands, except per share amounts)

slide-48
SLIDE 48

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 48

Footnotes to Non-GAAP Reconciliation

slide-49
SLIDE 49

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 49

Non-GAAP Reconciliation

4Q19 Income from Continuing Operations and Diluted EPS Reconciliation – Detailed View

($ in thousands, except per share amounts)

slide-50
SLIDE 50

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 50

Non-GAAP Reconciliation

YTD Income from Continuing Operations and Diluted EPS Reconciliation – Detailed View

($ in thousands, except per share amounts)

slide-51
SLIDE 51

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 51

Non-GAAP Reconciliation

EBITDA and Adjusted EBITDA Reconciliation

($ in thousands)

slide-52
SLIDE 52

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 52

Non-GAAP Reconciliation

Organic Sales Growth Rate Reconciliation (% Change)

slide-53
SLIDE 53

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 53

12/31/19 Original 12/31/19 As Reported Rate Rate Cash & Cash Equivalents 13 $ $200M Revolver [Due 2022]

  • $

L + 325 L + 200 TLA [Due 2022] 267 $ L + 325 L + 200 TLB [Due 2022] 558 $ L + 425 L + 250 Total Principal Amount of Debt Outstanding 825 $ Deferred Fees and OID (10) $ Total Debt (Principal Amount of Debt Outstanding Less Deferred Fees and Discounts) 815 $ Net Total Debt (Principal Amount of Debt Outstanding Less Cash) 812 $ Continuing Operations Statistics Trailing 4 Quarter Adjusted EBITDA 284 $ Trailing 4 Quarter Cash Interest Expense 45 $ Trailing 4 Quarter Capital Expenditures 48 $ Credit Statistics Net Total Debt / Trailing 4 Quarter Adjusted EBITDA 2.9x Trailing 4 Quarter Adjusted EBITDA / Cash Interest Expense 6.3x

(1) (1) Principal amount of debt outstanding, not reduced for unamortized discount and debt issuance costs (2) Leverage calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by trailing 4 quarter Adjusted EBITDA (2)

Capitalization

($ in millions)

slide-54
SLIDE 54

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 54

Non-GAAP Reconciliation for Fiscal Year 2017 & 2016

GAAP income from continuing operations to Adj. EBITDA from continuing operations

($ in thousands)

slide-55
SLIDE 55

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 55

Non-GAAP Reconciliation for Fiscal Year 2017 & 2016

GAAP income from total operations to Adj. EBITDA from total operations

($ in thousands)

slide-56
SLIDE 56

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 56

Non-GAAP Reconciliation for Fiscal Year 2017

YTD Income from Continuing Operations and Diluted EPS Reconciliation – Detailed View

($ in thousands, except per share amounts)

slide-57
SLIDE 57

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 57

Non-GAAP Reconciliation for Fiscal Year 2017

GAAP net income and diluted EPS to adjusted amounts

($ in thousands, except per share amounts)

slide-58
SLIDE 58

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 58

Non-GAAP Reconciliation for Fiscal Year 2017

GAAP net income and diluted EPS to adjusted amounts – detailed view

($ in thousands, except per share amounts)

(a) (a)

slide-59
SLIDE 59

ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 59

Contact Information

Tony Borowicz

SVP, Strategy, Business Development & Investor Relations

Integer

Tony.Borowicz@Integer.net www.integer.net

(O) 716.759.5809